This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
Voluntarily sign a written informed consent (ICF).
Age ≥ 18 years at enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Life expectancy ≥ 3 months.
Gastrointestinal obstruction.
Anorexia due to difficulty in eating caused by neurosis, mental illness, or pain.
Comorbidities such as severe cerebrovascular, cardiac, renal, or liver diseases.
Major surgery or trauma within the last month.
Changchun GeneScience Pharmaceutical Co., Ltd.
Lead sponsor